Organization Overview
Alternative names
allogeneic hematopoietic stem cells (Hemacord) (6 trials)
bortezomib (velcade) (1 trial)
cabazitaxel (jevtana kit) (1 trial)
cyclophosphamide (cytoxan) (4 trials)
docetaxel (taxotere) (4 trials)
epirubicin (ellence) (2 trials)
allogeneic lymphocytes (3 trials)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (4 trials)
apalutamide (erleada) (1 trial)
autologous hematopoietic stem cells (2 trials)
cyclosporine (sandimmune) (3 trials)
cytarabine (cytosar-u) (2 trials)
daunorubicin (cerubidine) (1 trial)
durvalumab (imfinzi) (1 trial)
immune globulin (human) (Gamastan) (1 trial)
Laromustine (onrigin) (1 trial)
lenalidomide (revlimid) (1 trial)
micafungin (mycamine) (1 trial)
Acute Disease (Phase 1)
Adenocarcinoma (Phase 3)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Colorectal Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 3)
Graft vs Host Disease (Phase 2)
Hematologic Diseases (Phase 2)
Inflammatory Breast Neoplasms (Phase 3)
Invasive Fungal Infections (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Multiple Myeloma (Phase 3)
Mycoses (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 3)
Pancreatic Neoplasms (Phase 3)
Plasmacytoma (Phase 2)
Precancerous Conditions (Phase 2)
Preleukemia (Phase 2)
Prostatic Neoplasms (Phase 3)
Rectal Neoplasms (Phase 3)
Recurrence (Phase 3)
Stomach Neoplasms (Phase 2)
Syndrome (Phase 2)
Urinary Bladder Neoplasms (Phase 2)